Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic ...
Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...
MedPage Today on MSN
GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes
ORLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective ...
Primary care and emergency medicine clinicians should familiarize themselves with common ophthalmologic conditions that, with timely referral and treatment, may help to improve vision. Ischemic optic ...
Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity ...
Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.
A 53-year-old man presented to the hospital after losing vision in his left eye. He explained that he had been given his second dose of Pfizer's COVID vaccine (Comirnaty) 10 days previously. He said ...
Optic atrophy is a condition in which the optic nerve begins to deteriorate. The optic nerve is the nerve at the back of your eye that connects your eye to your brain, allowing you to see. There are a ...
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today ...
Ischemic optic neuropathies are the most common acute optic nerve pathology in patients older than 50 years of age. A 62-year-old Asian man presents to the emergency department with a complaint of ...
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results